At the 12th Aging Research & Drug Discovery (ARDD) Meeting, which is being held this week in Copenhagen, Life Biosciences Inc. announced that it is developing its partial epigenetic reprogramming technology for liver disease as well as optic neuropathies. The company’s chief scientific officer Sharon Rosenzweig-Lipson estimated that its ER-100 would enter clinical trials in early 2026, putting it on track to be the first application of partial epigenetic reprogramming to enter the clinic. Read More

It is known that phosphatidylinositol 5-phosphate 4-kinase, type II, γ (PIP4K2C) is a lipid kinase tied to poor outcomes in a variety of cancers, such as colorectal (CRC) and breast cancers. In the search for PIP4K2C degraders, researchers from Larkspur Biosciences Inc. discovered LRK-4189, a cereblon-mediated PIP4K2C degrader. Read More

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded $1.1 million to Phiogen Inc. to evaluate PHI-BI-01, the company’s dual-action therapeutic designed to treat and prevent extraintestinal pathogenic Escherichia coli (ExPEC) bloodstream infections. Read More

CDT Equity Inc. has deployed an AI-led drug repurposing strategy for its portfolio and identified a new biological target and novel therapeutic indication for its lead program, AZD-1656 (and its derivatives). Read More

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) targeting moiety via a linker reported to be useful for the treatment of cancer. Read More

Pfizer Inc. provided details on the discovery and in vitro/in vivo characteristics of SIK inhibitor PF-07899895 for the treatment of inflammatory bowel disease (IBD). Pfizer’s program focused on pan-SIK inhibition to regulate cytokine production in immune cells based on the hypothesis that this approach could suppress pro-inflammatory cytokines/chemokines and promote an anti-inflammatory phenotype. Read More

Lineage Cell Therapeutics Inc. has entered into a research collaboration with William Demant Invest A/S to develop Lineage’s auditory neuronal cell transplant Resonance (ANP-1) for hearing loss. Read More

Ensem Therapeutics Inc. has disclosed phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly PI3Kα mutant inhibitors, reported to be useful for the treatment of cancer. Read More

Genescience Pharmaceuticals Co. Ltd. has identified camptothecin derivatives acting as DNA topoisomerase I inhibitors reported to be useful for the treatment of cancer. Read More

Aging is marked by a gradual decline in body function, partly driven by the buildup of senescent cells. These cells stop dividing but release a mix of inflammatory and tissue-remodeling factors, known as the senescence-associated secretory phenotype (SASP). Read More

Hinova Pharmaceuticals Inc. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, hepatic steatosis and polycystic ovary syndrome. Read More

Foresight Therapeutics (Hefei) Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Read More

Hypoxia is a common event in the microenvironment of solid tumors, triggering some changes in gene expression profiles to adapt to low-oxygen levels. Increasing evidence exists regarding hypoxia and mitochondrial dysfunction to play a role in the progression of non-small-cell lung cancer (NSCLC). Read More